{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T07:03:56Z","timestamp":1789974236024,"version":"4.0.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,3,1]],"date-time":"2027-03-01T00:00:00Z","timestamp":1803859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,3,1]],"date-time":"2027-03-01T00:00:00Z","timestamp":1803859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2027,3]]},"DOI":"10.1016\/j.vhri.2026.101653","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T20:09:43Z","timestamp":1780603783000},"page":"101653","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cost-Effectiveness Analysis of Anamorelin and Olanzapine for Cancer Cachexia in Non-Small Cell Lung Cancer Patients in Japan"],"prefix":"10.1016","volume":"58","author":[{"given":"Munenobu","family":"Kashiwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.vhri.2026.101653_bib1","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.vhri.2026.101653_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.advnut.2024.100282","article-title":"Prevalence of and survival with cachexia among patients with cancer: a systematic review and meta-analysis","volume":"15","author":"Takaoka","year":"2024","journal-title":"Adv Nutr"},{"issue":"1","key":"10.1016\/j.vhri.2026.101653_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.105","article-title":"Cancer-associated cachexia","volume":"4","author":"Baracos","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"10.1016\/j.vhri.2026.101653_bib4","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1080\/01635581.2025.2492126","article-title":"The prevalence and prognostic impact of cancer cachexia on overall survival in patients with gastrointestinal cancer: a meta-analysis","volume":"77","author":"Zhang","year":"2025","journal-title":"Nutr Cancer"},{"issue":"5","key":"10.1016\/j.vhri.2026.101653_bib5","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1002\/jcsm.13323","article-title":"Diagnosis and outcomes of cachexia in Asia: working Consensus Report from the Asian Working Group for Cachexia","volume":"14","author":"Arai","year":"2023","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"14","key":"10.1016\/j.vhri.2026.101653_bib6","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1517\/14656566.2015.1079621","article-title":"Advances in pharmacologic strategies for cancer cachexia","volume":"16","author":"Madeddu","year":"2015","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"10.1016\/j.vhri.2026.101653_bib7","article-title":"Megestrol acetate for treatment of anorexia-cachexia syndrome","volume":"2019","author":"Ruiz Garcia","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.vhri.2026.101653_bib8","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.clnu.2016.12.003","article-title":"Association between cachexia, chemotherapy and outcomes in older cancer patients: a systematic review","volume":"36","author":"Caillet","year":"2017","journal-title":"Clin Nutr"},{"issue":"4","key":"10.1016\/j.vhri.2026.101653_bib9","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(15)00558-6","article-title":"Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials","volume":"17","author":"Temel","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.vhri.2026.101653_bib10","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S1470-2045(14)71154-4","article-title":"Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials","volume":"16","author":"Garcia","year":"2015","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.vhri.2026.101653_bib11","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1093\/annonc\/mdx192","article-title":"3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia","volume":"28","author":"Currow","year":"2017","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.vhri.2026.101653_bib12","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/cncr.31128","article-title":"Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04)","volume":"124","author":"Katakami","year":"2018","journal-title":"Cancer"},{"issue":"14","key":"10.1016\/j.vhri.2026.101653_bib13","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1200\/JCO.22.01997","article-title":"Randomized double-blind placebo-controlled study of olanzapine for chemotherapy-related anorexia in patients with locally advanced or metastatic gastric, hepatopancreaticobiliary, and lung cancer","volume":"41","author":"Sandhya","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.vhri.2026.101653_bib14","doi-asserted-by":"crossref","first-page":"385","DOI":"10.6004\/jnccn.2025.7033","article-title":"Olanzapine for anorexia in patients with incurable cancer and cachexia (OlAnCa): a double-blind, placebo-controlled, randomized clinical trial","volume":"23","author":"Othman","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.vhri.2026.101653_bib15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jval.2019.10.005","article-title":"Formal implementation of cost-effectiveness evaluations in Japan: a unique health technology assessment system","volume":"23","author":"Hasegawa","year":"2020","journal-title":"Value Health"},{"issue":"10083","key":"10.1016\/j.vhri.2026.101653_bib16","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(17)30873-5","article-title":"Future and potential spending on health 2015-40: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries","volume":"389","author":"Global Burden of Disease Health Financing Collaborator Network","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.vhri.2026.101653_bib17","first-page":"1201","article-title":"Trends in medical expenses for ocular examinations in Japan based on nationwide database studies","volume":"8","author":"Kanaya","year":"2025","journal-title":"JMA J"},{"issue":"3","key":"10.1016\/j.vhri.2026.101653_bib19","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/jgf2.422","article-title":"Data resource profile: JMDC claims database sourced from health insurance societies","volume":"22","author":"Nagai","year":"2021","journal-title":"J Gen Fam Med"},{"issue":"2","key":"10.1016\/j.vhri.2026.101653_bib20","doi-asserted-by":"crossref","first-page":"58","DOI":"10.37737\/ace.23008","article-title":"A review of studies using Japanese nationwide administrative claims databases","volume":"5","author":"Sato","year":"2023","journal-title":"Ann Clin Epidemiol"},{"issue":"21","key":"10.1016\/j.vhri.2026.101653_bib21","doi-asserted-by":"crossref","first-page":"5405","DOI":"10.3390\/cancers14215405","article-title":"Cancer cachexia among patients with advanced non-small-cell lung cancer on immunotherapy: an observational study with exploratory gut microbiota analysis","volume":"14","author":"Hakozaki","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.vhri.2026.101653_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-048232","article-title":"Proxy responses regarding quality of life of patients with terminal lung cancer: preliminary results from a prospective observational study","volume":"12","author":"Takura","year":"2022","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.vhri.2026.101653_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2016-000151","article-title":"Health-related quality of life in a randomized phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study","volume":"2","author":"Hagiwara","year":"2017","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.vhri.2026.101653_bib24","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1477-7525-6-84","article-title":"Health state utilities for non small cell lung cancer","volume":"6","author":"Nafees","year":"2008","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"10.1016\/j.vhri.2026.101653_bib25","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s40273-023-01319-x","article-title":"Estimating costs associated with disease model states using generalized linear models: a tutorial","volume":"42","author":"Zhou","year":"2024","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.vhri.2026.101653_bib26","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s40273-019-00771-y","article-title":"An educational review about using cost data for the purpose of cost-effectiveness analysis","volume":"37","author":"Franklin","year":"2019","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.vhri.2026.101653_bib27","series-title":"Medical fee schedule 2024 (Ika Shinryo Houshu Tensu-hyo; medical services). Revision of Medical Fees","year":"2024"},{"key":"10.1016\/j.vhri.2026.101653_bib28","series-title":"National Health Insurance Drug Price Standard 2025","year":"2024"},{"key":"10.1016\/j.vhri.2026.101653_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2020.601329","article-title":"Nutritional interventions in cancer cachexia: evidence and perspectives from experimental models","volume":"7","author":"van de Worp","year":"2020","journal-title":"Front Nutr"},{"issue":"8","key":"10.1016\/j.vhri.2026.101653_bib30","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.3390\/ijerph19084604","article-title":"Nutritional and exercise interventions in cancer-related cachexia: an extensive narrative review","volume":"19","author":"Clemente-Su\u00e1rez","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"10.1016\/j.vhri.2026.101653_bib31","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/jcsm.12351","article-title":"Feasibility of early multimodal interventions for elderly patients with advanced pancreatic and non-small-cell lung cancer","volume":"10","author":"Naito","year":"2019","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"3","key":"10.1016\/j.vhri.2026.101653_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/jcsm.13871","article-title":"A randomized trial of nutrition and Exercise Treatment in patients with pancreatic and non-small cell lung cancer (NEXTAC-TWO)","volume":"16","author":"Mitsunaga","year":"2025","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"3","key":"10.1016\/j.vhri.2026.101653_bib33","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1136\/bmjspcare-2017-001440","article-title":"Cancer cachexia: rationale for the MENAC (Multimodal-Exercise, Nutrition and anti-inflammatory medication for cachexia) trial","volume":"8","author":"Solheim","year":"2018","journal-title":"BMJ Support Palliat Care"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109926000683?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109926000683?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:29:52Z","timestamp":1789972192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109926000683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,3]]},"references-count":32,"alternative-id":["S2212109926000683"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2026.101653","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2027,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness Analysis of Anamorelin and Olanzapine for Cancer Cachexia in Non-Small Cell Lung Cancer Patients in Japan","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2026.101653","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society for Pharmacoeconomics and Outcomes Research, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101653"}}